Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA Biosciences, the biotech has agreed to sell the deals to an investment ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. The Dow is a highly recognized and influential stock market index that ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money, recently ...

Harrisburg’s Spring Gate Spirits distillery is undergoing changes in ownership and location. York County-based Allegro Wine Company LLC Owner Carl Helrich has taken ownership interest in Spring Gate ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

The federal Pipeline and Hazardous Materials Safety Administration said the line poses, a “risk to public safety, property, ...

Behind Winrevair, the most promising clinical-stage program in Merck's pipeline is a cholesterol drug tentatively named MK-0616. The company started a 17,000-patient phase 3 program to test MK ...

Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics (SWTX), Reuters’ Sabrina Valle ...